| Literature DB >> 24726367 |
Avraham Maimon1, Maxim Mogilevsky1, Asaf Shilo1, Regina Golan-Gerstl1, Akram Obiedat1, Vered Ben-Hur1, Ilana Lebenthal-Loinger1, Ilan Stein2, Reuven Reich3, Jonah Beenstock4, Eldar Zehorai5, Claus L Andersen6, Kasper Thorsen6, Torben F Ørntoft6, Roger J Davis7, Ben Davidson8, David Mu9, Rotem Karni10.
Abstract
The kinase Mnk2 is a substrate of the MAPK pathway and phosphorylates the translation initiation factor eIF4E. In humans, MKNK2, the gene encoding for Mnk2, is alternatively spliced yielding two splicing isoforms with differing last exons: Mnk2a, which contains a MAPK-binding domain, and Mnk2b, which lacks it. We found that the Mnk2a isoform is downregulated in breast, lung, and colon tumors and is tumor suppressive. Mnk2a directly interacts with, phosphorylates, activates, and translocates p38α-MAPK into the nucleus, leading to activation of its target genes, increasing cell death and suppression of Ras-induced transformation. Alternatively, Mnk2b is pro-oncogenic and does not activate p38-MAPK, while still enhancing eIF4E phosphorylation. We further show that Mnk2a colocalization with p38α-MAPK in the nucleus is both required and sufficient for its tumor-suppressive activity. Thus, Mnk2a downregulation by alternative splicing is a tumor suppressor mechanism that is lost in some breast, lung, and colon tumors.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24726367 DOI: 10.1016/j.celrep.2014.03.041
Source DB: PubMed Journal: Cell Rep Impact factor: 9.423